India is about to set a Minimum Import Price (MIP) for Penicillin‑G, a key ingredient for many common antibiotics.
The move aims to keep domestic manufacturers from being undercut by very low‑priced imports, mainly from China. The price ceiling will apply only to imports meant for the Indian market and will be reviewed after about a year.
Aurobindo Pharma has poured more than ₹2,500 crore into a new Pen‑G/6‑APA plant under the Production‑Linked Incentive (PLI) scheme. With a stable import price, the company can run the plant profitably and increase local supply of penicillin‑based APIs.
International Pen‑G prices have fallen to around $13.5 per kilogram, far below the estimated $25 kg cost of Indian production. Without the MIP, local makers would struggle to compete.
The government recently set an MIP of $180 kg for Potassium Clavulanate (KGA), another crucial antibiotic ingredient. This was done to support the first Indian producer, Kinvan Pvt. Ltd., which is scaling up to 300 metric tonnes a year.
Most penicillin‑based medicines are price‑controlled by the government, so any cost rise at the raw‑material level is likely to be absorbed without a noticeable impact on retail prices. The MIP is a temporary, targeted tool, not a permanent trade barrier.
Major pharma groups such as the Indian Pharmaceutical Alliance and the Bulk Drugs Manufacturers Association support the measure, citing the strategic risk of over‑dependence on a single source. A few import‑focused firms have voiced opposition.
The proposed MIP provides a breathing space for Indian manufacturers to grow capacity, protect jobs, and move the country toward self‑sufficiency in essential antibiotic ingredients.
Remember, this is perspective, not a prediction. Do your own research before making any investment decisions.
Download the TradeKaizen app to practice F&O trading with real-time market data anytime, anywhere.
Get it on Google PlayConnect with fellow traders, share strategies, and improve your trading skills in our Telegram group.
Join TelegramRetail investors have become the biggest driver of India’s IPO frenzy this year, putting about ₹42,000 crore into primary market listings – the highest amount ever recorded. Why Retail Money Is Surging Individual investors are using phones and laptops to apply for new shares, a trend that has tripled the retail IPO money compared with 2023. Easy access to systematic investment plans (SIPs) and higher household incomes have given them more confidence to take on equity risk. Mutual Funds Add Another ₹38,000 crore Mutual funds, which channel huge SIP inflows from individuals, have contributed an extra ₹38,000 crore to IPOs. This makes retail money the single biggest source of funding for new listings. Regulatory Structure Helps Retail Participation Dedicated retail quota: Every IPO reserves a portion just for individual investors. Allocation method: Oversubscribed issues use proportionate or lucky‑draw allotment, keeping risk low. Low downside: Even if a few IPOs underperform, gains from strong listings usually offset the loss. How India Stands Apart Globally Retail participation in Indian IPOs is far higher than in the US or Europe, where institutions dominate. The Indian market now resembles places like Hong Kong, South Korea and China, where individuals play a major role. Foreign Portfolio Investors (FPIs) Still Active FPIs have also increased their primary‑market exposure, investing about ₹45,700 crore this year – close to the total retail amount. They are attracted by fresh entry points and better‑valued high‑growth companies. What This Means for Traders For everyday traders, the retail‑led surge means more IPO opportunities and a market that rewards long‑term equity exposure. Because retail allocation limits are built‑in, the risk of overexposure in a single issue is reduced. Remember, this is perspective, not a prediction. Do your own research and consider your risk tolerance before investing in any IPO.
India’s IPO market has quieted down as the year ends, with just one fresh issue to subscribe and a dozen companies ready to list. Only New Issue This Week Modern Diagnostic and Research Centre (MDRC) is opening a Rs 37 crore SME IPO on December 31, closing on January 2, and aims to list on January 7. The offer is priced between Rs 85–90 per share, valuing the diagnostics chain at roughly Rs 136 crore. MDRC runs 21 centres across eight states and posted a 55 % profit jump in FY 25, thanks to its asset‑light model. 11 Companies Set to List While fresh fundraising is scarce, the spotlight shifts to the 11 firms scheduled to debut, most on SME platforms. Grey‑market pricing shows mixed sentiment: Shyam Dhani Industries – strongest buzz, trading at a 100 % GMP, suggesting a possible double‑up on debut after a 988‑times oversubscription. E to E Transportation Infrastructure – quoted at a 75‑80 % premium, backed by a solid rail‑systems order book. Gujarat Kidney and Super Speciality – the sole main‑board listing, Rs 251 crore issue subscribed 5.2 times, but trading at a flat premium. Other listings show modest or flat premiums, indicating cautious optimism despite heavy oversubscription in some cases. What Investors Are Watching Grey‑market activity suggests investors are picking a few names they expect to outperform, while staying prudent on the broader batch of listings. Looking Ahead to 2026 Even with a slow finish to 2025, the pipeline for next year looks robust. Over Rs 2 lakh crore of IPOs are already approved or awaiting clearance, including big players such as Reliance Jio and PhonePe. Market participants expect a surge in activity once trading fully resumes in January. In the coming weeks, Bharat Coking Coal (BCCL), a subsidiary of Coal India, may launch a pure “offer‑for‑sale” IPO, putting around 46.57 crore shares on the market. Proceeds will go to the parent, not to BCCL itself. Other potential listings include Fractal, touted as India’s first AI‑focused IPO, and Hero Fincorp, a leading NBFC. Bottom Line For now, investors have limited new subscriptions but a handful of promising listings to watch. The real action is likely to pick up in early 2026, when large‑cap issuers re‑enter the market. Remember, this is just an overview, not a recommendation. Do your own research before making any investment decisions.
The Indian government wants Coal India’s eight subsidiaries to be listed on stock exchanges by 2030, aiming for better governance and value creation. Government Push for Listings The Prime Minister's Office has asked the coal ministry to map and list every subsidiary of Coal India Ltd (CIL) by 2030. The goal is to improve transparency, tighten governance and unlock value through asset monetisation. Subsidiaries Set for IPOs Coal India operates through eight subsidiaries: Eastern Coalfields Ltd Bharat Coking Coal Ltd (BCCL) Central Coalfields Ltd Western Coalfields Ltd South Eastern Coalfields Ltd (SECL) Northern Coalfields Ltd Mahanadi Coalfields Ltd Central Mine Planning & Design Institute Ltd (CMPDI) Key upcoming listings: BCCL and CMPDI are expected to list by March 2026 after completing domestic and international roadshows. South Eastern Coalfields Ltd (SECL) and Mahanadi Coalfields Ltd have been directed to list within the next financial year. Both BCCL and CMPDI have already filed draft red‑herring prospectuses (DRHP) with SEBI for an offer‑for‑sale (OFS) of shares. BCCL’s OFS could involve up to 46.57 crore equity shares. What This Means for Investors Listing these subsidiaries could bring several benefits: Greater transparency and corporate governance standards. Potential for new investment opportunities as the shares become publicly tradable. Possible unlock of hidden value in assets that were previously held within the state‑run structure. Coal India itself is targeting a production of 875 million tonnes of coal for the current financial year, underscoring its central role in India’s energy supply. Remember, this is perspective, not a prediction. Do your own research before making any investment decisions.